STOCK TITAN

[8-K] MEDICAL PROPERTIES TRUST INC Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Medical Properties Trust (MPW) furnished third‑quarter 2025 results and announced a new stock repurchase program. The board approved the repurchase of up to $150 million of common stock.

Repurchases may occur through open market purchases, Rule 10b5‑1 trading plans, privately negotiated transactions, structured or derivative transactions, other equity contracts, or other permitted methods. The company is under no obligation to repurchase any shares and may begin, suspend, or terminate activity at any time at its discretion, considering liquidity, market conditions, regulatory factors, and the marginal benefit of new investments or debt reduction.

The press release covering financial results for the three and nine months ended September 30, 2025, and supplemental information were furnished as exhibits.

Medical Properties Trust (MPW) ha riportato i risultati del terzo trimestre 2025 e ha annunciato un nuovo programma di riacquisto di azioni. Il consiglio di amministrazione ha approvato il riacquisto di un massimo di $150 milioni di azioni ordinarie.

I riacquisti possono avvenire tramite acquisti sul mercato aperto, piani di trading Rule 10b5‑1, transazioni negoziate privatamente, transazioni strutturate o differenziate, altri contratti azionari o altri metodi ammessi. La società non ha alcun obbligo di riacquistare azioni e può iniziare, sospendere o terminare l'attività in qualsiasi momento a sua discrezione, tenendo conto della liquidità, delle condizioni di mercato, dei fattori normativi e del beneficio marginale di nuovi investimenti o riduzione del debito.

Il comunicato stampa che riporta i risultati finanziari per i tre e i nove mesi conclusi al 30 settembre 2025, e le informazioni supplementari sono stati forniti come allegati.

Medical Properties Trust (MPW) informó los resultados del tercer trimestre de 2025 y anunció un nuevo programa de recompra de acciones. La junta aprobó la recompra de hasta $150 millones de acciones ordinarias.

Las recompras pueden efectuarse a través de compras en el mercado abierto, planes de negociación Rule 10b5‑1, transacciones negociadas en privado, transacciones estructuradas o derivadas, otros contratos de equity u otros métodos permitidos. La empresa no tiene obligación de recomprar acciones y puede comenzar, suspender o finalizar la actividad en cualquier momento a su discreción, considerando la liquidez, las condiciones de mercado, factores regulatorios y el beneficio marginal de nuevas inversiones o reducción de deuda.

El comunicado de prensa que cubre los resultados financieros de los tres y nueve meses terminados el 30 de septiembre de 2025, y la información suplementaria se proporcionaron como anexos.

Medical Properties Trust (MPW)는 2025년 3분기 실적을 발표했고 새로운 자사주 매입 프로그램을 발표했습니다. 이사회는 보통주 최대 $150백만의 매입을 승인했습니다.

매입은 공개 시장 매입, Rule 10b5‑1 거래 계획, 비공개 협상 거래, 구조화 또는 파생 거래, 기타 주식 계약 또는 허용된 방법으로 이루어질 수 있습니다. 회사는 주식 매입에 대해 의무가 없으며 필요에 따라 유동성, 시장 상황, 규제 요인, 신규 투자의 한계 이익 또는 부채 감소를 고려하여 언제든지 시작, 중단 또는 종료할 수 있습니다.

2025년 9월 30일로 종료된 3개월 및 9개월의 재무 결과를 다루는 보도자료와 보충 정보가 첨부로 제공되었습니다.

Medical Properties Trust (MPW) a publié les résultats du troisième trimestre 2025 et a annoncé un nouveau programme de rachat d’actions. Le conseil d’administration a approuvé le rachat d’un maximum de $150 millions d’actions ordinaires.

Les rachats peuvent avoir lieu par le biais d’achats sur le marché libre, de plans de négociation Rule 10b5‑1, de transactions négociées en privé, de transactions structurées ou dérivées, d’autres contrats sur actions ou d’autres méthodes autorisées. L’entreprise n’est pas tenue de racheter des actions et peut commencer, suspendre ou mettre fin à cette activité à tout moment à sa discrétion, en tenant compte de la liquidité, des conditions de marché, des facteurs réglementaires et du bénéfice marginal de nouveaux investissements ou de la réduction de la dette.

Le communiqué de presse couvrant les résultats financiers des trois et neuf mois terminés le 30 septembre 2025, ainsi que les informations complémentaires ont été fournis en tant qu’annexes.

Medical Properties Trust (MPW) hat die Ergebnisse des dritten Quartals 2025 veröffentlicht und ein neues Aktienrückkaufprogramm angekündigt. Das Vorstands­gremium hat den Rückkauf von bis zu $150 Millionen Stammaktien genehmigt.

Rückkäufe können durch Kauf im offenen Markt, Rule 10b5‑1-Handelspläne, privat ausgehandelte Transaktionen, strukturierte oder derivative Transaktionen, andere Eigenkapitalverträge oder andere zulässige Methoden erfolgen. Das Unternehmen ist nicht verpflichtet, Aktien zurückzukaufen, und kann die Aktivität jederzeit nach eigenem Ermessen beginnen, aussetzen oder beenden, unter Berücksichtigung von Liquidität, Marktbedingungen, regulatorischen Faktoren sowie dem zusätzlichen Nutzen neuer Investitionen oder der Schuldenreduzierung.

Die Pressemitteilung, die die Finanzergebnisse für die drei und neun Monate zum 30. September 2025 abdeckt, und ergänzende Informationen wurden als Anhänge bereitgestellt.

Medical Properties Trust (MPW) أعلنت نتائج الربع الثالث من 2025 واعتمدت برنامجاً جديداً لإعادة شراء الأسهم. وافق مجلس الإدارة على إعادة شراء ما يصل إلى $150 مليون من الأسهم العادية.

قد تتم عمليات إعادة الشراء من خلال الشراء في السوق المفتوح، وخطط التداول Rule 10b5‑1، والمعاملات التي يتم التفاوض عليها بشكل خاص، أو المعاملات الهيكلية أو المشتقة، أو غيرها من العقود المصاحبة للأسهم، أو غيرها من الأساليب المسموح بها. ليس على الشركة أي التزام بإعادة شراء أي أسهم وقد تبدأ أو suspends أو terminate النشاط في أي وقت وفقاً لتقديرها، مع مراعاة السيولة وظروف السوق والعوامل التنظيمية والفائدة الحدية للاستثمارات الجديدة أو خفض الدين.

تم توفير البيان الصحفي الذي يغطي النتائج المالية للثلاثة أشهر والـ9 أشهر المنتهية في 30 سبتمبر 2025، بالإضافة إلى معلومات تكميلية كـ Exhibits.

Positive
  • None.
Negative
  • None.

Insights

$150M buyback adds optionality; execution discretionary.

Medical Properties Trust authorized up to $150,000,000 in common stock repurchases. The plan lists multiple pathways—open market purchases, Rule 10b5‑1 plans, privately negotiated and structured/derivative transactions—providing flexibility across trading conditions.

The authorization imposes no purchase obligation and can be started, paused, or terminated at the company’s discretion. Actual activity will depend on liquidity, market conditions, regulatory considerations, and relative benefits versus new investments or debt reduction, as stated.

The company also furnished Q3 2025 results and a supplemental package as exhibits. Any impact on leverage or share count will hinge on subsequent execution and disclosed amounts in future updates.

Medical Properties Trust (MPW) ha riportato i risultati del terzo trimestre 2025 e ha annunciato un nuovo programma di riacquisto di azioni. Il consiglio di amministrazione ha approvato il riacquisto di un massimo di $150 milioni di azioni ordinarie.

I riacquisti possono avvenire tramite acquisti sul mercato aperto, piani di trading Rule 10b5‑1, transazioni negoziate privatamente, transazioni strutturate o differenziate, altri contratti azionari o altri metodi ammessi. La società non ha alcun obbligo di riacquistare azioni e può iniziare, sospendere o terminare l'attività in qualsiasi momento a sua discrezione, tenendo conto della liquidità, delle condizioni di mercato, dei fattori normativi e del beneficio marginale di nuovi investimenti o riduzione del debito.

Il comunicato stampa che riporta i risultati finanziari per i tre e i nove mesi conclusi al 30 settembre 2025, e le informazioni supplementari sono stati forniti come allegati.

Medical Properties Trust (MPW) informó los resultados del tercer trimestre de 2025 y anunció un nuevo programa de recompra de acciones. La junta aprobó la recompra de hasta $150 millones de acciones ordinarias.

Las recompras pueden efectuarse a través de compras en el mercado abierto, planes de negociación Rule 10b5‑1, transacciones negociadas en privado, transacciones estructuradas o derivadas, otros contratos de equity u otros métodos permitidos. La empresa no tiene obligación de recomprar acciones y puede comenzar, suspender o finalizar la actividad en cualquier momento a su discreción, considerando la liquidez, las condiciones de mercado, factores regulatorios y el beneficio marginal de nuevas inversiones o reducción de deuda.

El comunicado de prensa que cubre los resultados financieros de los tres y nueve meses terminados el 30 de septiembre de 2025, y la información suplementaria se proporcionaron como anexos.

Medical Properties Trust (MPW)는 2025년 3분기 실적을 발표했고 새로운 자사주 매입 프로그램을 발표했습니다. 이사회는 보통주 최대 $150백만의 매입을 승인했습니다.

매입은 공개 시장 매입, Rule 10b5‑1 거래 계획, 비공개 협상 거래, 구조화 또는 파생 거래, 기타 주식 계약 또는 허용된 방법으로 이루어질 수 있습니다. 회사는 주식 매입에 대해 의무가 없으며 필요에 따라 유동성, 시장 상황, 규제 요인, 신규 투자의 한계 이익 또는 부채 감소를 고려하여 언제든지 시작, 중단 또는 종료할 수 있습니다.

2025년 9월 30일로 종료된 3개월 및 9개월의 재무 결과를 다루는 보도자료와 보충 정보가 첨부로 제공되었습니다.

Medical Properties Trust (MPW) a publié les résultats du troisième trimestre 2025 et a annoncé un nouveau programme de rachat d’actions. Le conseil d’administration a approuvé le rachat d’un maximum de $150 millions d’actions ordinaires.

Les rachats peuvent avoir lieu par le biais d’achats sur le marché libre, de plans de négociation Rule 10b5‑1, de transactions négociées en privé, de transactions structurées ou dérivées, d’autres contrats sur actions ou d’autres méthodes autorisées. L’entreprise n’est pas tenue de racheter des actions et peut commencer, suspendre ou mettre fin à cette activité à tout moment à sa discrétion, en tenant compte de la liquidité, des conditions de marché, des facteurs réglementaires et du bénéfice marginal de nouveaux investissements ou de la réduction de la dette.

Le communiqué de presse couvrant les résultats financiers des trois et neuf mois terminés le 30 septembre 2025, ainsi que les informations complémentaires ont été fournis en tant qu’annexes.

Medical Properties Trust (MPW) hat die Ergebnisse des dritten Quartals 2025 veröffentlicht und ein neues Aktienrückkaufprogramm angekündigt. Das Vorstands­gremium hat den Rückkauf von bis zu $150 Millionen Stammaktien genehmigt.

Rückkäufe können durch Kauf im offenen Markt, Rule 10b5‑1-Handelspläne, privat ausgehandelte Transaktionen, strukturierte oder derivative Transaktionen, andere Eigenkapitalverträge oder andere zulässige Methoden erfolgen. Das Unternehmen ist nicht verpflichtet, Aktien zurückzukaufen, und kann die Aktivität jederzeit nach eigenem Ermessen beginnen, aussetzen oder beenden, unter Berücksichtigung von Liquidität, Marktbedingungen, regulatorischen Faktoren sowie dem zusätzlichen Nutzen neuer Investitionen oder der Schuldenreduzierung.

Die Pressemitteilung, die die Finanzergebnisse für die drei und neun Monate zum 30. September 2025 abdeckt, und ergänzende Informationen wurden als Anhänge bereitgestellt.

Medical Properties Trust (MPW) أعلنت نتائج الربع الثالث من 2025 واعتمدت برنامجاً جديداً لإعادة شراء الأسهم. وافق مجلس الإدارة على إعادة شراء ما يصل إلى $150 مليون من الأسهم العادية.

قد تتم عمليات إعادة الشراء من خلال الشراء في السوق المفتوح، وخطط التداول Rule 10b5‑1، والمعاملات التي يتم التفاوض عليها بشكل خاص، أو المعاملات الهيكلية أو المشتقة، أو غيرها من العقود المصاحبة للأسهم، أو غيرها من الأساليب المسموح بها. ليس على الشركة أي التزام بإعادة شراء أي أسهم وقد تبدأ أو suspends أو terminate النشاط في أي وقت وفقاً لتقديرها، مع مراعاة السيولة وظروف السوق والعوامل التنظيمية والفائدة الحدية للاستثمارات الجديدة أو خفض الدين.

تم توفير البيان الصحفي الذي يغطي النتائج المالية للثلاثة أشهر والـ9 أشهر المنتهية في 30 سبتمبر 2025، بالإضافة إلى معلومات تكميلية كـ Exhibits.

MEDICAL PROPERTIES TRUST INC false 0001287865 0001287865 2025-10-30 2025-10-30
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): October 30, 2025

 

 

MEDICAL PROPERTIES TRUST, INC.

(Exact Name of Registrant as Specified in Charter)

 

 

Commission File Number 001-32559

 

Maryland   20-0191742

(State or other jurisdiction

of incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

1000 Urban Center Drive, Suite 501

Birmingham, AL

  35242
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code

(205) 969-3755

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol

 

Name of each exchange

on which registered

Common Stock, par value $0.001 per share, of Medical Properties Trust, Inc.   MPW   The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company   

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 


Item 2.02. Results of Operations and Financial Condition.

On October 30, 2025, Medical Properties Trust, Inc. issued a press release announcing its financial results for the three and nine months ended September 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including the information set forth in Exhibit 99.1 and Exhibit 99.2 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. In addition, this information shall not be deemed incorporated by reference in any filing of Medical Properties Trust, Inc. with the Securities and Exchange Commission, except as expressly set forth by specific reference in any such filing.

Item 8.01. Other Events.

On October 28, 2025, the board of directors of Medical Properties Trust, Inc. (the “Company”) approved a stock repurchase program (the “Stock Repurchase Program”) for up to $150 million of common stock, par value $0.001 per share, of the Company (the “Shares”). Repurchases may be effected from time to time through open market purchases (including trading plans that may be adopted in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended), privately negotiated transactions, structured or derivative transactions, other equity contracts or other methods of acquiring shares.

The Company is under no obligation to repurchase any Shares and will evaluate any opportunities to do so in the context of the Company’s future liquidity profile, prevailing market conditions and regulatory considerations, as well as the potential marginal benefit of new investments and/or debt reduction. The Company may, in its discretion, begin, suspend or terminate repurchases at any time prior to the expiration of the Stock Repurchase Program, without any prior notice.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit Number   

Description

99.1    Press release dated October 30, 2025 reporting financial results for the three and nine months ended September 30, 2025
99.2    Medical Properties Trust, Inc. 3rd Quarter 2025 Supplemental Information
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

2


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunder duly authorized.

 

MEDICAL PROPERTIES TRUST, INC.

By:  

/s/ R. Steven Hamner

Name:   R. Steven Hamner
Title:   Executive Vice President and Chief Financial Officer

Date: October 30, 2025

 

3

FAQ

What did MPW announce in its latest 8-K?

MPW furnished Q3 2025 results and approved a stock repurchase program for up to $150 million of common stock.

How large is Medical Properties Trust’s new buyback?

The board authorized repurchases of up to $150 million of common stock.

What methods can MPW use to repurchase shares?

Open market purchases, Rule 10b5-1 trading plans, privately negotiated transactions, structured or derivative transactions, other equity contracts, and other lawful methods.

Is MPW required to repurchase shares under this program?

No. The company is under no obligation and may begin, suspend, or terminate repurchases at any time.

What financial materials did MPW provide with the announcement?

A press release with results for the three and nine months ended September 30, 2025, and a Q3 2025 supplemental information package.

What factors will influence MPW’s repurchase activity?

The company cited future liquidity, market conditions, regulatory considerations, and the marginal benefit of new investments and/or debt reduction.
Medical Prop

NYSE:MPW

MPW Rankings

MPW Latest News

MPW Latest SEC Filings

MPW Stock Data

2.92B
497.01M
17.3%
59.5%
27.66%
REIT - Healthcare Facilities
Real Estate Investment Trusts
Link
United States
BIRMINGHAM